Takeda Pharmaceutical Company Limited American Depositary Receipt (TKDA)

Overview

Takeda Pharmaceutical Company Limited stands tall as a beacon in the pharmaceutical industry, tracing its origins back to 1781. With its global headquarters in Tokyo, Japan, Takeda is dedicated to the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Its reach spans both Japan and international markets, testifying to its commitment towards enhancing healthcare around the world. Its portfolio encompasses an array of therapeutic areas including gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. Takeda distinguishes itself through strategic collaborations, licensing agreements, and research partnerships with various entities in the healthcare and biotechnology sectors such as BioMarin, Luxna Biotech, GlaxoSmithKline, Neurocrine Biosciences, Inc., Seagen Inc., and many more. These alliances serve to bolster Takeda’s innovative capabilities and expand its impact on patient care globally.

Products and Services

Takeda Pharmaceutical Company Limited provides a broad spectrum of pharmaceutical products and services catered to diverse medical needs. Some of its notable products include:

• Entyvio: A key product in the area of gastroenterology, offering relief and treatment for specific gastrointestinal conditions.
• Gattex/Revestive, Takecab/Vocinti: Targeting rare gastrointestinal disorders, these products exemplify Takeda’s commitment to addressing less common, but challenging health issues.
• Alofisel, Dexilant, Pantoloc/Controloc: These products further underline Takeda’s strength in developing treatments within the gastroenterological field, offering options for various digestive health concerns.
• Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine: Part of Takeda’s plasma-derived therapies, these products are crucial in treating certain blood disorders, showcasing the company’s contribution to hematological care.
• Takhzyro, Livtencity: Takeda offers these innovative solutions in the realm of immunology, aiming to improve the lives of patients dealing with immune system-related diseases.
• Elaprase, Replagal: In the fight against rare diseases, these therapies represent Takeda’s dedication to providing hope and solutions to patients confronted with less common medical conditions.
• Advate, Flexbumin, Vpriv: These products reflect Takeda’s ongoing efforts to address a variety of health challenges, including but not limited to, hematology and genetic disorders.
• Gammagard Liquid/Kiovig, Hyqvia, Cuvitru: Emphasizing the company’s prowess in immunology, these therapies are aimed at supporting patients with compromised immune systems.
• Exkivity, Ninlaro, Velcade: Oncology is another critical area for Takeda, with these products leading the charge against cancer, offering patients hope and improved outcomes.
• Azilva-F, Lotriga: Dedicating efforts towards cardiovascular health, these medicines provide options for managing high blood pressure, a common concern globally.
• Iclusig, Leuplin/Enantone, Adcetris: Targeting specific types of cancer, these products are part of Takeda’s robust oncology portfolio, aimed at offering specialized treatment options.
• vyvanse/elvanse, Trintellix, Alunbrig: Takeda’s presence in the neuroscience domain is highlighted through these therapies, addressing mental health and neurological conditions.

Through these products and more, Takeda Pharmaceutical Company Limited continues to impact various therapeutic areas, showing its versatility and dedication to improving patient health across the globe.